Chugai Pharmaceutical Co., Ltd. (4519) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.62 M

Shareholding (Mar 2025)

FII

0.00%

Held by 2 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 23.71%

Healthy long term growth as Net Sales has grown by an annual rate of 11.43% and Operating profit at 19.46%
Company has very low debt and has enough cash to service the debt requirements

The company has declared Positive results for the last 4 consecutive quarters

With ROE of 21.74%, it has a attractive valuation with a 6.45 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

JPY 11,106,966 Million (Large Cap)

P/E

30.00

Industry P/E

Dividend Yield

0.02%

Debt Equity

-0.52

Return on Equity

20.52%

Price to Book

5.60

Revenue and Profits:

Net Sales:

290,005 Million

(Quarterly Results - Jun 2025)

Net Profit:

97,155 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

25.78%

6 Months

9.4%

1 Year

24.33%

2 Years

56.09%

3 Years

130.55%

4 Years

126.38%

5 Years

66.92%

Chugai Pharmaceutical Co., Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Chugai Pharmaceutical Co., Ltd. Reports Strong Financial Performance in Q2 2025

Chugai Pharmaceutical Co., Ltd. has demonstrated impressive financial results for the quarter ending June 2025, showcasing a robust operational performance that has caught the attention of investors. The company, recognized as a large-cap entity, has reported its highest operating cash flow to date, amounting to JPY 464,601 MM.

In addition to its strong cash flow, Chugai Pharmaceutical has also declared a record dividend per share for the half-year, set at JPY 3.59. This reflects the company's commitment to returning value to its shareholders, further evidenced by a significant dividend payout ratio of 211.73%.

The financial health of Chugai Pharmaceutical is further underscored by its substantial cash and equivalents, which stand at JPY 1,972,159 MM. This strong liquidity position allows the company to navigate market fluctuations effect...

Chugai Pharmaceutical Hits Day Low Amid Price Pressure, Shares at JPY 6,917.00

Chugai Pharmaceutical Co., Ltd. saw a significant stock price decline today, contrasting with the broader market's performance. Despite this downturn, the company maintains strong long-term fundamentals, including a high Return on Equity and consistent growth in net sales and operating profit, alongside low debt levels and solid cash reserves.

Chugai Pharmaceutical Hits Day Low at JPY 6,975 Amid Price Pressure

Chugai Pharmaceutical Co., Ltd. saw its stock price decline significantly today, contrasting with the broader market's performance. Despite this drop, the company maintains strong fundamentals, including a high Return on Equity and consistent positive results over recent quarters, supported by low debt and healthy cash reserves.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

11.43%

EBIT Growth (5y)

19.46%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.50

Sales to Capital Employed (avg)

0.69

Tax Ratio

29.16%

Dividend Payout Ratio

41.63%

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

52.96%

ROE (avg)

23.71%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

6.45

EV to EBIT

19.52

EV to EBITDA

19.42

EV to Capital Employed

11.81

EV to Sales

9.30

PEG Ratio

1.23

Dividend Yield

0.01%

ROCE (Latest)

60.50%

ROE (Latest)

21.74%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.54% vs -4.51% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -0.08% vs 6.20% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "290,005.00",
          "val2": "288,459.00",
          "chgp": "0.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "148,362.00",
          "val2": "146,872.00",
          "chgp": "1.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-12,400.00",
          "val2": "-2,400.00",
          "chgp": "-416.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "97,155.00",
          "val2": "97,234.00",
          "chgp": "-0.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "483.70%",
          "val2": "481.40%",
          "chgp": "0.23%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 5.33% vs -11.79% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 19.00% vs -13.08% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,170,611.00",
          "val2": "1,111,367.00",
          "chgp": "5.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "575,572.00",
          "val2": "447,405.00",
          "chgp": "28.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "95.00",
          "val2": "82.00",
          "chgp": "15.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-8,992.00",
          "val2": "-15,310.00",
          "chgp": "41.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "387,317.00",
          "val2": "325,472.00",
          "chgp": "19.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "464.60%",
          "val2": "374.00%",
          "chgp": "9.06%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

290,005.00

288,459.00

0.54%

Operating Profit (PBDIT) excl Other Income

148,362.00

146,872.00

1.01%

Interest

0.00

Exceptional Items

-12,400.00

-2,400.00

-416.67%

Consolidate Net Profit

97,155.00

97,234.00

-0.08%

Operating Profit Margin (Excl OI)

483.70%

481.40%

0.23%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.54% vs -4.51% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -0.08% vs 6.20% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

1,170,611.00

1,111,367.00

5.33%

Operating Profit (PBDIT) excl Other Income

575,572.00

447,405.00

28.65%

Interest

95.00

82.00

15.85%

Exceptional Items

-8,992.00

-15,310.00

41.27%

Consolidate Net Profit

387,317.00

325,472.00

19.00%

Operating Profit Margin (Excl OI)

464.60%

374.00%

9.06%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 5.33% vs -11.79% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 19.00% vs -13.08% in Dec 2023

All Annual Results

Company CV

About Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Chugai Pharmaceutical Co., Ltd.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 23.71%

The company has declared Positive results for the last 4 consecutive quarters

With ROE of 21.74%, it has a attractive valuation with a 6.45 Price to Book Value

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Chugai Pharmaceutical Co., Ltd. Reports Strong Financial Performance in Q2 2025

Chugai Pharmaceutical Hits Day Low Amid Price Pressure, Shares at JPY 6,917.00

Chugai Pharmaceutical Hits Day Low at JPY 6,975 Amid Price Pressure

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Chugai Pharmaceutical Co., Ltd.

Company Coordinates